<DOC>
	<DOCNO>NCT00101933</DOCNO>
	<brief_summary>The purpose research study safety effectiveness bilateral stimulation anterior nucleus thalamus adjunctive therapy reduce frequency seizure adult diagnose epilepsy characterize partial-onset seizure , without secondary generalization , refractory antiepileptic medication .</brief_summary>
	<brief_title>SANTE - Stimulation Anterior Nucleus Thalamus Epilepsy</brief_title>
	<detailed_description>Medtronic , Inc. sponsor investigational study Medtronic DBS Therapy epilepsy , company 's deep brain stimulation ( DBS ) therapy patient refractory epilepsy . Epilepsy condition affect 2.3 million Americans , one-third patient refractory , continue experience seizure despite wide range treatment option . The prospective , randomize , double-blind trial use exist technology test whether bilateral stimulation anterior nucleus thalamus safely effectively reduce seizure frequency patient epilepsy . It include enrollment 157 patient 17 site U.S. 110 patient implant monitor 13 month follow implant , long-term follow-up device approve study stop . 109 110 implanted subject randomize Active stimulation Control . Patients active group , receive neurostimulation , monitor reduction seizure rate compare control group , receive neurostimulation three-month double-blind phase . After double-blind phase , patient receive neurostimulation . Candidates trial adult partial-onset epilepsy least three antiepileptic drug proven ineffective . They average six seizure per month . Candidates continue receive epilepsy medication participate trial . Deep brain stimulation therapy already receive approval United States , Europe , Canada , Australia treatment Essential Tremor Parkinson 's disease . Deep brain stimulation approve United States treatment epilepsy .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Relevant Inclusion Exclusion Criteria list . Inclusion Criteria Partialonset seizures without secondary generalization . The final determination shall make Investigator base clinical description seizures previous diagnostic testing include , minimum , video/clinical EEG capture least one ictal event . Anticipated average 6 partialonset seizure ( without secondary generalized seizure ) per month Baseline Phase , 30 day seizure Baseline Phase . Refractory antiepileptic drug ( AEDs ) . Patients consider refractory fail least three AEDs due lack efficacy . Receiving one four currently market AEDs Be 18 65 year age time lead implant Multilobar ( &gt; 3 different lobe ) anatomic area seizure onset Symptomatic generalize epilepsy Previous diagnosis psychogenic/nonepileptic seizure Presence implant electrical stimulation medical device anywhere body ( e.g. , cardiac pacemaker , spinal cord stimulator ) metallic implant head ( e.g. , aneurysm clip , cochlear implant ) . Vagal nerve stimulators allow device turn least 30 day prior Baseline Week 12 visit patient agree generator explanted prior time Kinetra Neurostimulator implant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Direct brain stimulation , SANTE</keyword>
</DOC>